These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8707747)

  • 1. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
    Zanetti S; Usai D; Nonis A; Fadda G
    J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
    Jones RB; Ridgway GL; Boulding S; Hunley KL
    Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
    Zanetti S; Ungheri D; Castellani Pastoris M; Fadda G
    Drugs Exp Clin Res; 1987; 13(10):631-4. PubMed ID: 3428127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Susceptibility study on urogenital Chlamydia trachomatis to 19 kinds of antibiotics].
    Bai H; Dong J; Ning B
    Zhonghua Yi Xue Za Zhi; 1995 Jan; 75(1):11-4, 60. PubMed ID: 7600311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
    Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.
    Prasad ES; Wenman WM
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):135-6. PubMed ID: 8467625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
    Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
    Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antibacterial activity of a new 3-azinomethyl-rifamycin.
    Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
    Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
    Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.
    Treharne JD; Yearsley PJ; Ballard RC
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1393-4. PubMed ID: 2552911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).
    Dickinson JM; Mitchison DA
    Tubercle; 1990 Jun; 71(2):109-15. PubMed ID: 2120827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative resistance to erythromycin in Chlamydia trachomatis.
    Mourad A; Sweet RL; Sugg N; Schachter J
    Antimicrob Agents Chemother; 1980 Nov; 18(5):696-8. PubMed ID: 7447426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.
    Walsh M; Kappus EW; Quinn TC
    Antimicrob Agents Chemother; 1987 May; 31(5):811-2. PubMed ID: 3038010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of dirithromycin against Chlamydia trachomatis.
    Segreti J; Kapell KS
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2213-4. PubMed ID: 7811051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice].
    Sternak SL; Skerk V
    Med Glas (Zenica); 2010 Feb; 7(1):26-31. PubMed ID: 20387721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of fleroxacin against Chlamydia trachomatis.
    Steele-Mortimer O; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():65-70. PubMed ID: 3144551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective inhibition of rifampicin-resistant Chlamydia trachomatis by the novel DNA-dependent RNA polymerase inhibitor corallopyronin A.
    Shima K; Ledig S; Loeper N; Schiefer A; Pfarr K; Hoerauf A; Graspeuntner S; Rupp J
    Int J Antimicrob Agents; 2018 Oct; 52(4):523-524. PubMed ID: 30092271
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
    Miyashita N; Matsumoto A; Matsushima T
    Microbiol Immunol; 2000; 44(4):267-9. PubMed ID: 10832970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of dirithromycin against Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Sokolovskaya N; Hammerschlag MR
    J Antimicrob Chemother; 1997 May; 39(5):647-9. PubMed ID: 9184366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.